CDK4 and breast carcinoma: Clinically, SY-5609 is undergoing evaluation in early-phase trials (e.g., NCT04247126) for treatment-refractory solid tumors, including advanced HR + breast cancer following CDK4/6i failure, pancreatic ductal adenocarcinoma, and biliary tract malignancies.